Privacy masthead desktop

Datenschutz - Bestimmungen

Effective: May 1, 2020

Your privacy is important to us at STAAR Surgical Company ("STAAR"). This privacy statement ("Statement") applies to STAAR Web sites, any mobile applications ("Apps") and digital platforms and services ("Services") (collectively, "Sites") and explains how we collect, use, disclose and otherwise process information that identifies you or from which you are identifiable (“Personal Information”). Please be sure to read this entire Statement before using or submitting information to our Sites.

Personal Information Collected We collect information from you in various ways when you use our Sites. We may collect Personal Information you directly provide on our Sites. In addition, we may collect Personal Information you generate as a user of our Sites or if you are a patient, which you provide to a healthcare professional or an institutional healthcare provider (collectively, "Providers"). Personal Information we may collect includes name, email address, phone number, gender, date of birth and zip code.

Where we collect and process Personal Information about your health or medical status (i.e., “Sensitive Personal Information”) this information may be subject to stricter requirements than other Personal Information. Before providing (or consenting to the disclosure of) Sensitive Personal Information to us, we urge you to carefully consider whether to disclose such information.

In addition, some information may be automatically collected when you visit our Sites – please see Section on Cookies below.

If you are a Provider, you are responsible for providing adequate notice to, and obtaining any legally required authorization, consent or other permission from, your patients prior to providing their Personal Information to STAAR through the Sites (though STAAR does not request patient Personal Information). By submitting any Personal Information about a patient to STAAR, you represent and warrant to STAAR that you have provided adequate notice to and obtained all required consents from patients to do so.

Interactive Services

If you choose to participate in our questionnaires and surveys and other interactive Services, we will collect Personal Information that you disclose, to help us better understand how STAAR products are used in addressing visual conditions for which they are marketed.

The information you provide through interactive Services may be combined (subject to all applicable laws) with the Personal Information provided elsewhere in or through the Services. We may combine your and others' Personal Information to create summary data that we will use for our business purposes, such as research to improve our products and analyses that may help us better market our products.

If you submit Sensitive Personal Information (e.g., health-related information) through the Services to participate in a clinical trial, sweepstake or otherwise, we may use such Sensitive Personal Information to assess whether you qualify for enrollment or participation, to contact you about potential participation, and to provide you with additional information.

You may provide information to be published or displayed ("Posted") on public areas of the Services (collectively, "User Contribution"). If you post User Contributions then you do so at your own risk. STAAR does not control the actions of third parties with access to your User Contributions.

Cookies We may automatically collect certain information through the use of "cookies." Cookies are small data files that are stored on your hard drive by a Web site, which the site may then use to identify you on your next visit. Among other things, the use of cookies helps us to improve our Sites and your experience. We use cookies to see which areas and features are most popular, to count the number of computers accessing our Sites, to personalize your experience, and to remember your preferences.

A "web beacon" is a piece of code that enables us to monitor user activity and website traffic. A "cookie" is a randomly-generated unique numeric code stored in the user's web browser settings or computer's hard drive. A cookie typically contains the name of the domain (internet location) from which the cookie originated, the "lifetime" of the cookie (i.e., when it expires), as well as the randomly generated unique numeric code.

We link the information we store in cookies to any personally identifiable information you submit while on our Sites. If you prefer not to receive cookies on this website, you can set your browser (such as internet explorer, Google Chrome, Mozilla Firefox, etc.) to warn you before accepting cookies and refuse the cookie when your browser alerts you to its presence. You can set your browser not to accept cookies, but if you do so or if you reject a cookie, you may not be able to access some of the features or services of our Sites. We may track your activities over time and across third-party websites, apps or other online services to display advertisements on third-party websites. If you do not want us to use your information in this way, please see "Your Privacy Choices" below. For more information about our digital advertising practices, please see "Digital Advertising" below.

If our third party vendors, consultants and other service providers ("Service Providers") use cookies, their use is not covered by this privacy statement. We do not have access or control over those cookies. Our Service Providers use session ID cookies to collect data in order to enable us to provide a better user experience.

Google, as a third party vendor, uses cookies to serve ads. Google's use of the first party cookies (such as Google Analytics cookies) and third-party cookies (such as the DoubleClick cookie) enables it to serve ads to you based on your visit to our Sites and other sites on the Internet. Additionally, these cookies are used to generate a report on how our ad impressions, other uses of ad services, and interactions with these ad impressions and ad services are related to visits to our Sites. Users may opt out of the use of the cookie by visiting the Google ad and content network privacy Statement here: or http://optout.networkadvertisi....

Facebook Pixel. We use Facebook Pixel on our Discover ICL site to track visits to the site and to analyze the content a Facebook user has viewed when visiting the Discover ICL site (e.g., EVO Visian ICL videos) in order to measure, optimize and improve the content of the site. This Pixel records information about a Facebook user's session on the Discover ICL website, which it sends to Facebook, along with an anonymised version of the user’s Facebook ID. We collect and store information gathered from the session Facebook Pixel cookie for 180 days. You can delete the Facebook Pixel cookie and other cookies at any time by clearing your browser cache. For further information about the Facebook Pixel please see:

Facebook Lead Ad: We use the Facebook Lead Ad to collect users’ full name, email address, city, and postal zip code. STAAR uses this data to contact the user via e-mail to send contact information about Visian ICL certified clinic(s). The user’s data will not be transmitted to the clinics in this process.

Connecting with Social Media through the Services

Certain Services may link with social media platforms and social media plug-ins (e.g., the Facebook "Like" button, "Share to Twitter" button) (collectively, "Social Media"). When accessing the Services through a Facebook or other Social Media account, STAAR may (depending on the applicable user privacy settings) automatically have access to information provided to or through the Social Media platform. STAAR may collect and use this information for the purposes described in this Privacy Statement or at the time the information was collected.

Connecting with Social Media through Service Providers

Third parties that assist us with our business operations also collect and use information (including Personal Information and "Usage Data" (i.e., information about an individual's activity on or through the Services that, by itself, does not identify the individual, such as browser type, operating system and webpages visited)) through the Services and also may share the collected information with us. For example, our vendors collect and share information with us to analyze use of the Services, to help us detect and prevent fraud and to improve user experience.

Sind Sie bereit, visuelle Freiheit mit der ICL zu entdecken? Finden Sie noch heute einen Arzt

Wichtige Sicherheitsinformationen

Denken Sie daran, dass die implantierbaren EVO Visian® Collamer®-Linsen (ICL) von der zuständigen Gesundheitsbehörde zugelassen wurden, was bedeutet, dass sie für sicher und wirksam befunden wurden. Wie bei allen Eingriffen sind Risiken zu berücksichtigen. Wenn Sie Fragen oder Bedenken haben, besprechen Sie diese am besten mit einem zugelassenen Arzt für implantierbare EVO Visian® Collamer®-Linsen (ICL). Die EVO Visian ICL-Linsenproduktreihe umfasst die EVO Visian ICL, die torische EVO Visian ICL, die EVO+ Visian ICL, die torische EVO+ Visian ICL und die Visian ICL und dient zur Korrektur/Reduktion von leichter bis starker Kurzsichtigkeit (-0,5 bis -20,0 Dioptrien (dpt)) und zur Korrektur/Reduktion von Kurzsichtigkeit bei Patienten mit bis zu -20 dpt mit höchstens 6,0 dpt Astigmatismus. Die Visian ICL dient zur Korrektur/Reduktion von leichter bis starker Weitsichtigkeit (+0,5 bis +10,0 Dioptrien(dpt)) und zur Korrektur/Reduktion von Weitsichtigkeit bei Patienten mit bis zu +10 dpt mit höchstens 6,0 dpt Astigmatismus. Die EVO Visian ICL-Produktreihe dient zur Korrektur/Reduktion der Kurzsichtigkeit bei Erwachsenen im Alter von 21-60 Jahren mit Werten von -0,5 dpt bis -20,0 dpt auf Brillenebene und Korrektur/Reduktion der Weitsichtigkeit bei Erwachsenen im Alter von 21-45 Jahren mit Werten von +0,5 dpt bis +10,0 dpt auf Brillenebene. Mit einer Tiefe der vorderen Kammer von 2,8mm oder mehr bei Kurzsichtigkeit und 3,0mm bei Weitsichtigkeit, gemessen vom Hornhautendothel zur vorderen Linsenkapsel. Der erweiterte Altersbereich von 45 bis 60 Jahren gilt nur für die kurzsichtige EVO Visian ICL-Produktreihe und nur in Ländern im Zuständigkeitsbereich der benannten Stellen der EU, in denen die CE-Kennzeichnung anerkannt wird (d.h. EU, EWR, EFTA). Die gegenwärtig im Bestand befindliche EVO Visian ICL-Produktreihe ist noch nicht mit der aktualisierten Gebrauchsanleitung mit diesem neuen Wortlaut versehen, doch wird dies im Laufe der Zeit geschehen. Die EVO Visian ICL-Operation macht eine Lesebrille nicht überflüssig, selbst wenn Sie bisher keine Lesebrille getragen haben. Die EVO Visian ICL-Operation stellt eine Alternative zu anderen refraktiven Operationen wie LASIK (Laser-in-situ-Keratomileusis), photorefraktive Keratektomie (PRK), Inzisionsoperationen oder anderen Mitteln zur Korrektur von Kurzsichtigkeit und Weitsichtigkeit wie Kontaktlinsen und Brillen, dar. Die torische EVO Visian ICL dient zur Korrektur oder Reduzierung eines möglichen Astigmatismus bis zu 6,0 dpt (die EVO Visian ICL dient nicht zur Behandlung von Astigmatismus). Die Implantation einer EVO Visian ICL ist ein chirurgischer Eingriff und daher mit potenziell schwerwiegenden Risiken verbunden. Die nachstehenden potenziellen Komplikationen/Nebenwirkungen sind allgemein im Zusammenhang mit refraktiven Operationen berichtet worden: weitere Operationen, Kataraktbildung, Verlust des bestkorrigierten Visus, erhöhter Augeninnendruck, Zellverlust an der innersten Hornhautoberfläche, Bindehautreizung, akute Hornhautschwellung, anhaltende Hornhautschwellung, Endophthalmitis (Infektion des gesamten Auges), signifikante Blendungsempfindlichkeit und/oder Lichthöfe, Hyphäma (Blut im Auge), Hypopyon (Eiter im Auge), Augeninfektion, Verlagerung der Visian ICL, Makulaödem, nicht reagierende Pupille, Pupillenblock-Glaukom, schwere Augenentzündung, Iritis, Uveitis, Glaskörperverlust und Hornhauttransplantat. Bevor Sie eine EVO Visian ICL-Operation in Betracht ziehen, sollten Sie sich einer vollständigen Augenuntersuchung unterziehen und die EVO Visian ICL-Operation, insbesondere die potenziellen Nutzen, Risiken und Komplikationen, mit Ihrem Augenarzt besprechen. Erkundigen Sie sich auch nach der erforderlichen Heilungsdauer nach der Operation.



1. Patient Survey, STAAR Surgical ICL Data Registry, 2018

2. Sanders D. Vukich JA. Comparison of implantable collamer lens (ICL) and laser-assisted in situ keratomileusis (LASIK) for Low Myopia. Cornea. 2006 Dec; 25(10):1139-46. Patient Survey, STAAR Surgical ICL Data Registry, 2018

3. Naves, J.S. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery. Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2012.

4. Shoja, MR. Besharati, MR. Dry eye after LASIK for myopia: Incidence and risk factors. European Journal of Ophthalmology. 2007; 17(1): pp. 1-6.

5a. Lee, Jae Bum et al. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. Journal of Cataract & Refractive Surgery , Volume 26 , Issue 9 , 1326 - 1331.

5b. Parkhurst, G. Psolka, M. Kezirian, G. Phakic intraocular lens implantantion in United States military warfighters: A retrospective analysis of early clinical outcomes of the Visian ICL. J Refract Surg. 2011;27(7):473-481.

*American Refractive Surgery Council